Axillary Lymph, Axillary Lymph Node Dissection, Breast Cancer, Neoadjuvant Systemic Therapy, Pathological Complete Response
Conditions
Keywords
Breast Cancer, Neoadjuvant Systemic Therapy, Axillary Surgery
Brief summary
This prospective, single-arm, phase II trial studies axillary lymph node dissection (ALND) to see if it can be safely omitted in breast cancer patients with axillary pathological complete response (pCR) after neoadjuvant systemic therapy (NST). Breast cancer patients with biopsy-proven positive axillary lymph nodes at initial diagnosis, and converted to negative after NST, which is confirmed by Stained region Lymph Node Biopsy(SrLNB), will be enrolled in the study. In other words, a total of 92 patients will be exempted from ALND after SrLNB, and afterwards complete regional node irradiation (RNI) including the axilla. They will also undergo adjuvant chemotherapy, targeted therapy, endocrinotherapy after surgery. These patients will be followed up in the next three years for local-regional recurrence and long-time survival outcome.
Interventions
PROCEDUREStained region Lymph Node Biopsy (SrLNB)
Before NST, carbon nanoparticles suspension would be injected into the cortex of positive lymph nodes for staining under ultrasound guidance. Marked lymph nodes will be removed and biopsied after NST.
RADIATIONRegional lymph node radiotherapy (RNI) including the axilla
RNI including the axilla covers the supraclavicular region and entire axillary lymphatic drainage area (region I, II and III) ,and is at a dose of 50 Gy/25 times, with additional prophylactic irradiation of the internal breast lymphatic drainage area for eligible patients.
Sponsors
The First Affiliated Hospital with Nanjing Medical University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Female aged between 18 and 70 years; 2. Pathologically confirmed invasive breast cancer (regardless of pathological type) with a clinical stage cT1-3; 3. Pathologically confirmed positive axillary lymph nodes with a clinical stage of N1-3; 4. Receiving a full course of neoadjuvant therapy (including neoadjuvant chemotherapy, neoadjuvant targeted therapy, neoadjuvant immunotherapy); 5. Positive axillary lymph nodes successfully stained by carbon nanoparticles injection; 6. All patients are required to undergo immunohistochemical staining for Estrogen Receptor (ER), Progesterone Receptor (PR), human epidermal growth factor receptor 2 (HER2), Ki- 67 proliferation index, and further fluorescence in situ hybridization (FISH) should be performed in HER2 2+ cases; 7. Preoperative clinical assessment (including physical examination, imaging, with or without nomogram assessment) suggests positive axillary lymph nodes converted to negative (ycN0); 8. ECOG score 0 - 1; 9. Patients voluntarily participated in this study and signed the informed consent form
Exclusion criteria
1. Bilateral breast cancer; 2. Breast cancer during lactation period or pregnancy; 3. Physical examination or imaging examination confirmed presence of distant metastases; 4. Previous history of malignant tumor; 5. History of previous surgery on the affected axilla; or history of surgery affecting the function of the upper extremity; 6. History of radiation therapy to the breast or chest; 7. Positive incision margins for breast-conserving surgery/mastectomy; 8. Positive results of intraoperative rapid freeze pathology (including isolated tumor cells and micrometastases) for SrLNB (ypN+); 9. Those who unable to complete the full course of follow-up adjuvant therapy as prescribed for various reasons; 10. Aspartate transaminase (AST) and alanine transaminase (ALT) ≥ 1.5 times the upper limit of normal, alkaline phosphatase（ALP） ≥ 2.5 times the upper limit of normal, total bile ≥ 1.5 times the upper limit of normal, serum creatinine ≥ 1.5 times the upper limit of normal; Left Ventricular Ejection Fractions (LVEF) \< 50% in cardiac ultrasound; 11. Severe coagulation dysfunction, serious systemic disease, or uncontrolled infection; 12. Without personal freedom and independent civil capacity; 13. Those with mental disorders, addictions, who were not eligible for enrollment in the judgment of the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| iDFS: invasive Disease-Free Survival after breast surgery | Up to 3 years after surgery | Time interval from the surgery to invasive local-regional recurrence, distant metastasis, contralateral invasive breast cancer, or death from any cause. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| LRR: Local-Regional Recurrence after breast surgery | Up to 3 years after surgery | This includes both local and regional recurrences. Local recurrence is defined as recurrence in the ipsilateral breast, chest wall, skin or surgical scar. Regional recurrence is defined as recurrence in the affected lymphatic drainage area, including the axilla, supraclavicular region, subclavicular region, and internal mammary node area. |
| BCRL: Breast Cancer Related Lymphedema | Up to 3 years after surgery | Objective evaluation of upper limb lymphedema by arm circumference and bioelectrical impedance measurement. In our study, BCRL is diagnosed in two ways：① Relative Volume Change (RVC ) \>10% in the affected upper extremity. ②Bioelectrical impedance technology: the impedance ratio is defined as the ratio of the impedance of the healthy upper limb to the impedance of the affected upper limb, and BCRL is diagnosed when the patient's impedance ratio is higher than the mean + 2 standard deviations (SD) of healthy controls. When the two measurements are inconsistent, the former results shall prevail. |
| Quality of life (QoL) | Up to 3 years after surgery | Patients' subjective assessment of quality of life (QoL) using the Functional Assessment of Cancer Therapy-Breast (FACT-B) . FACT-B is divided into 36 items in 5 domains, namely: physical status (7 items), social/family status (7 items), emotional status (6 items), functional status (7 items) and additional concerns, and each item is classified into five levels: not at all (0), somewhat (1), somewhat (2), fairly (3) and very much (4). Positive items were scored directly from 0 to 4, while negative items (i.e., the larger the number of response options, the worse the quality of life) were scored in reverse. The total score of FACT-B scale ranges from 0 to 144, a higher score means a better quality of life for the patient. |
| Patient-reported arm morbidity | Up to 3 years after surgery | Patients' subjective assessment of lymphedema using the Quick Disability of the Arm, Shoulder, and Hand (Quick DASH) questionnaires，Quick DASH consists of 11 items, and is a self-rating scale of daily functioning including social functioning and physical activity and upper extremity symptoms. Each item is divided into 5 levels, and the patient's score is calculated as score = \[(patient score/number of response items) - 1\] × 25, with a total score of 0 to 100, and the higher the score, the greater the degree of upper limb dysfunction. |
Countries
China
Contacts
Primary ContactJue Wang, MD
Backup ContactLingjun Ma, MD
Outcome results
None listed